Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report

BMC Gastroenterology

Philipp Stockmann¹  Friedrich W Neukam¹  Falk Wehrhan¹  Martin Raithel²  Tobias Ebker¹  Raimund HM Preidl¹ 

[1]Department of Oral and Maxillofacial Surgery, University of Erlangen, Glückstraße 11, Erlangen 91054, Germany

[2]Department of Gastroenterology, Pneumology and Endocrinology, University of Erlangen, Erlangen, Germany

关键词: Crohn’s disease;    Adalimumab;    Bisphosphonate;    Osteonecrosis of the jaw;   

Others  :  856744
DOI  :  10.1186/1471-230X-14-6

 received in 2013-06-13, accepted in 2014-01-03,  发布年份 2014

【 摘 要 】

Background

Bisphosphonates have a widespread indication for osteoporosis and are also applied in cancer patients with skeletal-related conditions. Bisphosphonate-associated osteonecrosis of the jaw (BRONJ) is a feared side effect which is hard to treat and often affects patient´s quality of life in an extensive manner. Adalimumab (Humira®), a fully human recombinant antibody specific for tumor necrosis factor- α, is approved for treatment in patients with Inflammatory Bowel Disease like ulcerative colitis or Crohn’s disease.

Case presentation

In March 2013, a 36-year-old female presented with right-sided perimandibular swelling, recurrent facial pain and exposed necrotic bone after previous extraction of tooth 47. She had the medical history of Crohn’s disease for more than one decade with chronic active enterocolitis, fistula disease as well as previous oral manifestation and was currently treated with Adalimumab since September 2008. Due to steroid-induced osteoporosis, diagnosed in 2004, she received oral Bisphosphonates (Risedronate) from 2004 until 2007 followed by two infusions of Zoledronic acid in 2008 and 2009.

Conclusion

This patient with a medical history of Crohn’s disease and gastrointestinal remission under Adalimumab therapy presented with osteonecrosis of the jaw after suspended oral and intravenous Bisphosphonate therapy implicating that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity.

【 授权许可】

   
2014 Preidl et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Kamel HK: Update on osteoporosis management in long-term care: focus on bisphosphonates. J Am Med Dir Assoc 2007, 8:434-440.
• [2]Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer 2008, 98:1736-1740.
• [3]Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg 2009, 67:2-12.
• [4]Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1117.
• [5]Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS: Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J Oral Maxillofac Surg 2013, 71:513-519.
• [6]Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009, 35:119-130.
• [7]Marx RE, Cillo JE Jr, Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65:2397-2410.
• [8]Stockmann P, Nkenke E, Englbrecht M, Schlittenbauer T, Wehrhan F, Rauh C, Beckmann MW, Fasching PA, Kreusch T, Mackensen A, et al.: Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2013, 41:71-75.
• [9]Migliorati CA, Siegel MA, Elting LS: Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006, 7:508-514.
• [10]Stockmann P, Wehrhan F, Schwarz-Furlan S, Stelzle F, Trabert S, Neukam FW, Nkenke E: Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: an immunohistological study. J Transl Med 2011, 9:135. BioMed Central Full Text
• [11]Allen MR: Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs 2009, 189:289-294.
• [12]Kyrgidis A, Toulis KA: Denosumab-related osteonecrosis of the jaws. Osteoporos Int 2011, 22:369-370.
• [13]Ebker T, Rech J, von Wilmowsky C, Neukam FW, Stockmann P: Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology (Oxford) 2013, 52:218-220.
• [14]Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E: Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010, 18:449-460.
• [15]Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006, 12:6222s-6230s.
• [16]Nagano Y, Matsui H, Shimokawa O, Hirayama A, Nakamura Y, Tamura M, Rai K, Kaneko T, Hyodo I: Bisphosphonate-induced gastrointestinal mucosal injury is mediated by mitochondrial superoxide production and lipid peroxidation. J Clin Biochem Nutr 2012, 51:196-203.
• [17]Dryden GW Jr: Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther 2009, 9:967-974.
• [18]Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K: New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol 2013, 32:271-275.
• [19]Joyau C, Veyrac G, Dixneuf V, Jolliet P: Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012, 30:700-706.
• [20]Hauzeur JP, Malaise M, Gangji V: Osteonecrosis in inflammatory bowel diseases: a review of the literature. Acta Gastroenterol Belg 2009, 72:327-334.
• [21]Freeman HJ: Osteomyelitis and osteonecrosis in inflammatory bowel disease. Can J Gastroenterol 1997, 11:601-606.
• [22]Lanyi B, Dienes HP, Kruis W: Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication? Dtsch Med Wochenschr 2005, 130:1944-1947.
• [23]Klingenstein G, Levy RN, Kornbluth A, Shah AK, Present DH: Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther 2005, 21:243-249.
• [24]Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, et al.: Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111. e1102
• [25]Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, et al.: High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753.
• [26]Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, Garcia-Vicuna R: Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1675-1678.
• [27]Akhtar NH, Afzal MZ, Ahmed AA: Osteonecrosis of jaw with the use of denosumab. J Cancer Res Ther 2011, 7:499-500.
• [28]Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005, 21:251-258.
• [29]Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH: Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010, 25:1732-1738.
• [30]Gersemann M, Wehkamp J, Stange EF: Innate immune dysfunction in inflammatory bowel disease. J Intern Med 2012, 271:421-428.